Articles by Nichole Tucker
Reimacabtagene autoleucel has induced an overall response rate of 84% in r/r LBCL.
Detailed findings from SURPASS-ET including pharmacokinetic and biomarker data will be presented in the future.
A study's efficacy and safety findings show promise for lovo-cel as a one-time intervention for SCD with history of stroke.
This approval for patients aged 12 years and older was based on findings from the explorer7 phase III clinical trial.
The approval was based on the findings from the phase III MSB-GVHD001 clinical study.
Vibecotamab showed clinical activity in low-blast, high-risk myeloid diseases, including MDS and CMML.
Luspatercept led to decreases RBCT burden vs epoetin alfa in patients with LR-MDS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.